Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Hydrazone derivatives from Novo Nordisk useful for normalizing glucose levels

Sep. 2, 1999

Positive results for Symlin in phase III study in type II diabetes

Sep. 2, 1999

More on Lilly's GH secretagogue program, including clinical candidate

Sep. 1, 1999

RESPECT trial will evaluate effects of lipid reduction on stroke prevention

Sep. 1, 1999

Non-halogen-containing PDHK inhibitors designed at Novartis

Sep. 1, 1999

NDA for subcutaneous Repronex approved by FDA

Aug. 31, 1999

Muse approved in Spain

Aug. 31, 1999

Tularik discovers new PPAR-gamma modulators for treating diabetes

Aug. 30, 1999

Institute for Diabetes Discovery researchers synthesize an improved aldose reductase inhibitor

Aug. 27, 1999

Bone resorption inhibitors, vitronectin receptor antagonists prepared at HMR

Aug. 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...